# Progress Note 02 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Sun Yat-sen (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ET016-SYN
- Date: 2026-05-18
- Fictional facility: St. Posthumous Health Center
- Fictional author: Wen-Li Huang, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Results of the liver mass work-up and medical oncology consultation. **S**

## History of present illness

Mr. Sun returns two weeks after his first visit and is seen the same day by Dr. Choi of medical oncology. He had the multiphase CT eleven days ago, the MRI with MRCP a week ago and the ultrasound-guided core biopsy five days ago; the biopsy site was sore for a day. He asked to see the images and went through them with Dr. Huang and Dr. Choi. The ache under his right ribs is 2 of 10 on acetaminophen once or twice a day, and he is eating five small meals a day. He has had no jaundice, itching, dark urine, fever or vomiting. He is still working full days and asked for a plain account of the findings and the choices. **S**

| Element | Detail |
|---|---|
| Tests done | Multiphase CT, MRI with MRCP, core biopsy of the liver mass |
| Pain | 2 of 10 on acetaminophen once or twice a day |
| Appetite and weight | Five small meals a day; weight 60.6 kg |
| Associated signs and symptoms | No jaundice, itching, dark urine, fever, or vomiting |
| His request | To see the images and hear the findings and choices plainly |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Weight down a further 0.4 kg; tired in the evenings; no fever |
| Gastrointestinal | Positive | Ache under the right ribs, 2 of 10; early fullness; no vomiting, jaundice, or pale stools |
| Respiratory | Negative | No cough or breathlessness |
| Integumentary | Negative | No itching; biopsy site healed |

4 systems reviewed. **S**

## Current medications

- Acetaminophen 500 mg oral tablet, two tablets by mouth every 8 hours as needed for right upper abdominal ache; no more than 3,000 mg a day **S**

## Allergies

- No known allergy **S**

## Objective

BP 128/82 mmHg; pulse 86 bpm; respirations 16/min; temperature 36.8 °C; oxygen saturation 98% on room air; weight 60.6 kg; BMI 22.3 kg/m². All vital signs are synthetic.

ECOG performance status: 1. All results are synthetic.

## Change since baseline

- ECOG performance status: 1 at baseline, 1 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Thin, well; blood pressure 128/82, pulse 86; weight 60.6 kg; no jaundice |
| Abdomen | Firm, non-tender mass felt 4 cm below the right costal margin, moving with breathing; no ascites; no splenomegaly |
| Lymph nodes | No supraclavicular or umbilical nodes |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Adenocarcinoma of the gallbladder invading the liver** (C23). CT and MRI show a 7.1 cm mass arising from the gallbladder fundus and invading liver segments IVb and V, with gallstones and two enlarged hepatoduodenal ligament nodes (1.6 and 1.3 cm); the bile ducts are not dilated, the main portal vein and hepatic artery are free, and there are no other liver lesions. The liver is smooth, without cirrhosis. CT of the chest shows only a 6 mm calcified granuloma in the right upper lobe. The core biopsy shows moderately differentiated adenocarcinoma, CK7 positive, CK20 and CDX2 negative, consistent with a pancreatobiliary origin; with the imaging, this is a primary gallbladder adenocarcinoma, not a primary liver cancer. Alpha-fetoprotein is normal and CA 19-9 412 U/mL. Clinical T3 N1 M0 (stage IIIB) on imaging. Liver function is preserved: Child-Pugh A6 (albumin 3.4 g/dL), ALBI grade 2, bilirubin and INR normal. Dr. Choi recommends tumor board review and a staging laparoscopy before any attempt at resection, because peritoneal disease is often not seen on CT in this cancer, and genomic profiling of the biopsy tissue. He agreed. **S**
   - Tumor board review in two days.
   - Staging laparoscopy, with an implanted port under the same anesthetic, in about ten days.
   - Comprehensive genomic profiling of the biopsy tissue.
   - Specialist palliative care introduced; he would like to meet the team once staging is complete.
   - Acetaminophen and small frequent meals; dietitian appointment.
2. **Right upper quadrant abdominal mass with weight loss** (R19.01). Superseded by the biopsy diagnosis of gallbladder adenocarcinoma. **S**
   - Problem resolved.
3. **Resolved hepatitis B infection** (Z86.19). Hepatitis B surface antigen negative, total core antibody positive, surface antibody 85 mIU/mL, and HBV DNA undetectable (drawn with the CT): resolved past infection with no liver damage. Hepatitis C antibody negative. Chemotherapy and immunotherapy carry a small risk of reactivation; monitoring with prompt treatment is reasonable rather than routine antiviral prophylaxis. **S**
   - HBV DNA and ALT every 3 months during treatment and for 6 to 12 months after.
   - Entecavir at once if HBV DNA becomes detectable or surface antigen reappears.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Imaging | Multiphase contrast CT or MRI of the liver | At presentation of a liver mass | Completed today | Mass arises from the gallbladder and invades segments IVb and V; non-cirrhotic liver; no other liver lesions |
| Imaging | CT of the chest, abdomen and pelvis | At staging, then every 2 to 3 months on treatment | Completed today | Two enlarged hepatoduodenal ligament nodes; no distant disease on CT; 6 mm calcified lung granuloma |
| Laboratory | Core biopsy of the mass | When imaging cannot make the diagnosis (non-cirrhotic liver) | Completed today | Adenocarcinoma, CK7 positive, CK20 and CDX2 negative: pancreatobiliary origin |
| Laboratory | Alpha-fetoprotein | At presentation of a liver mass | Up to date | 3.2 ng/mL at intake; normal |
| Laboratory | CA 19-9 (and CEA when raised) | At diagnosis, then with each cycle or restaging | Up to date | CA 19-9 412 U/mL and CEA 8.6 ng/mL at intake |
| Laboratory | Liver function: Child-Pugh and ALBI | At diagnosis, then before each treatment decision | Completed today | Child-Pugh A6; ALBI grade 2; bilirubin 0.9 mg/dL and INR 1.0 at intake |
| Laboratory | Hepatitis B and C serology | Before chemotherapy or immunotherapy | Completed today | Surface antigen negative, core antibody positive, surface antibody positive, HBV DNA undetectable; hepatitis C antibody negative |
| Survey | ECOG performance status | Every visit | Completed today | ECOG 1 |
| Examination | Weight and nutrition | Every visit | Completed today | 60.6 kg, down 0.4 kg in two weeks; dietitian booked |
| Survey | Pain | Every visit | Completed today | 2 of 10 on acetaminophen |
| Referral | Multidisciplinary tumor board | Before treatment of a biliary tract cancer | Ordered | In two days |
| Imaging | Staging laparoscopy | Before resection of gallbladder cancer | Ordered | In about ten days, with a port |
| Laboratory | Comprehensive genomic profiling of tumor tissue | At diagnosis of advanced disease | Ordered | Sent on the biopsy tissue |
| Referral | Medical oncology | At diagnosis | Completed today | Seen by Dr. Choi today |
| Referral | Specialist palliative care | From the diagnosis of advanced cancer | Due | Introduced today; first meeting after staging, at his choice |

## Goal progress

- Tissue diagnosis and complete staging within four weeks of the first visit. In progress; target 2026-06-01. **S**
- Right upper abdominal pain at 3 of 10 or less, with full days of work possible (ECOG 0 to 1). In progress; target 2026-10-26. **S**
- Weight held within 2 kg of the weight at the start of treatment. In progress; target 2026-10-26. **S**
- Goals of care and a health care agent documented, and revisited as treatment changes. In progress; target 2026-09-21. **S**
- Complete first-line chemoimmunotherapy without grade 3 or higher toxicity. In progress; target 2026-10-26. **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026), National Comprehensive Cancer Network
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma (2023), American Association for the Study of Liver Diseases (Hepatology)
- Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update (2020), American Society of Clinical Oncology (Journal of Clinical Oncology)
- Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update (2017), American Society of Clinical Oncology (Journal of Clinical Oncology)

## Follow-up

- Tumor board in two days; staging laparoscopy in about ten days. Visit in two weeks with the result and the tumor board recommendation. **S**
- Next scheduled visit 2026-06-01: staging laparoscopy result and tumor board recommendation; first cycle of chemoimmunotherapy and specialist palliative care. **S**
